Novartis plans to make UK the global centre for its new inclisiran study. Credit: Novartis AG.

Novartis is planning to conduct a primary prevention study of inclisiran, a cholesterol-lowering drug, with the UK as the global trial centre.

The trial will take place in alliance with Oxford University, the NHS, and the National Institute for Health Research (NIHR).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the study, inclisiran will be assessed for its potential to improve cardiovascular outcomes by decreasing low-density lipoprotein cholesterol (LDL-C).

Novartis intends to leverage the approaches used to enrol 500,000 patients into the UK Biobank and the drug’s ongoing ORION-4 trial in heart attack or stroke patients.

Oxford University medicine professor John Bell said: “This new trial offers an important opportunity to test the ability of inclisiran to lower the risk of heart disease and stroke in a broad range of people.

“At the same time, it will demonstrate how a new generation of streamlined trials can provide reliable information about novel treatments for conditions that affect large numbers of NHS patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership between Novartis and the NHS will also see the development of a population health model to an at-risk patient population with atherosclerotic cardiovascular disease.

This model is intended to offer treatment to secondary prevention ASCVD patients who fail to achieve their LDL-C target on statins alone.

Concurrent with the trial announcement, Novartis formally opened its new UK headquarters in White City Place. The new headquarters is close to Imperial College London’s new research and innovation campus.

Novartis UK country president Haseeb Ahmad said: “White City is fast becoming one of the UK’s most exciting new hubs for life sciences, and puts us in the perfect position to continue working with our partners to find new ways to innovate and collaborate to build a healthier tomorrow.”